Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.47 |
| ▸ | THRA | P10827 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 4/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046383 | 1.00 | EGLN1 (0.47) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL523239 | 0.84 | EGLN1 (0.50) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL521962 | 0.83 | FTO (0.53) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL523213 | 0.83 | FTO (0.53) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL521963 | 0.83 | FTO (0.53) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL523022 | 0.81 | EGLN1 (0.51) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL523018 | 0.80 | EGLN1 (0.69) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL523019 | 0.80 | EGLN1 (0.69) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL522268 | 0.80 | THRA (0.72) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL524007 | 0.80 | EGLN1 (0.69) | EGLN1THRATHRBFTOBBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885THRA 3799/4885THRB 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.